A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects with Severe Coronavirus Disease 2019 (COVID-19)
Chadi Hage, MD
Primary Investigator
Overview
The purpose of this study is to evaluate the safety and efficacy of TJ003234 in subjects with severe COVID-19 with supportive care.
Description
Participants will be randomly assigned to receive either a single dose of 3 mg/kg TJ003234, a single dose of 6 mg/kg TJ00324, or placebo, administered by IV infusion. Participants will be monitored for 30 days following their last dose.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
COVID-19
-
Age: Between 18 Years - 100 Years
-
Gender: All
Individuals at least 18 years of age with laboratory confirmed diagnosis of COVID-19, with severe disease.
Individuals with certain comorbidities will not be eligible.
Women who are pregnant or breastfeeding will not be eligible.